“痰瘀互结”与肿瘤微环境:中医病机的现代生物学阐释
Phlegm-Stasis Intermingling and Tumor Microenvironment: A Modern Biological Elucidation of Traditional Chinese Medicine Pathogenesis
DOI: 10.12677/wjcr.2026.164028, PDF,   
作者: 代京玲:成都中医药大学临床医学院,四川 成都;熊绍权*:成都中医药大学附属医院,四川 成都
关键词: 痰瘀互结;肿瘤微环境;中医病机;免疫抑制;单细胞转录组学;Intermingling of Phlegm and Stasis; Tumor Microenvironment; TCM Pathogenesis; Immunosuppression; Single-Cell Transcriptomics
摘要: 目的:以中医“痰瘀互结”理论为基础,探讨其与肿瘤微环境病理机制之间的关系,为中医药调控肿瘤微环境提供理论依据。方法:采用文献梳理与理论分析的方法,阐述中医视角“痰瘀互结”的理论内涵及与肿瘤微环境在免疫抑制、血管生成异常、代谢重编程等方面的机制对应。结果:“痰瘀互结”在物质基础、功能效应和动态演进三个层面与肿瘤微环境的病理特征存在对应关系:痰浊类似于免疫抑制性细胞因子网络和代谢废物蓄积,瘀血类似于血管生成异常和细胞外基质重塑,痰瘀胶结的过程则与肿瘤微环境由免疫激活向免疫抑制的演进相类似。结论:“痰瘀互结”既是中医对肿瘤病理的宏观概括,也在一定程度上反映了肿瘤微环境的核心特征;单细胞转录组学可从细胞亚群层面为上述病机对应关系提供细胞学证据。
Abstract: Objective: Based on the traditional Chinese medicine (TCM) theory of phlegm-stasis intermingling (tanyu hujie), this study explores its correlation with the pathological mechanisms underlying the tumor microenvironment (TME), aiming to provide a theoretical basis for TME modulation with TCM. Methods: Literature review and theoretical analysis were adopted to interpret the theoretical connotation of phlegm-stasis intermingling from the TCM perspective, as well as its mechanistic correspondence with the TME in immunosuppression, aberrant angiogenesis, and metabolic reprogramming. Results: Phlegm-stasis intermingling corresponds to TME pathological features across three dimensions: material basis, functional outcome, and dynamic progression. Phlegm turbidity is analogous to the immunosuppressive cytokine network and accumulation of metabolic waste; blood-stasis mirrors aberrant angiogenesis and extracellular matrix remodeling; the binding of phlegm and stasis recapitulates the TME transition from immune-activated to immune-suppressed status. Conclusion: Phlegm-stasis intermingling represents not only a macroscopic TCM generalization of tumor pathology but also partly reflects core characteristics of the TME. Single-cell transcriptomics can furnish cytological evidence supporting the above-mentioned pathogenetic correspondence at the cellularsubset level.
文章引用:代京玲, 熊绍权. “痰瘀互结”与肿瘤微环境:中医病机的现代生物学阐释[J]. 世界肿瘤研究, 2026, 16(4): 268-275. https://doi.org/10.12677/wjcr.2026.164028

参考文献

[1] Ren, X., Zhang, L., Zhang, Y., Li, Z., Siemers, N. and Zhang, Z. (2021) Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment. Annual Review of Immunology, 39, 583-609.
https://doi.org/10.1146/annurev-immunol-110519-071134
[2] Chen, S., Zhou, Z., Li, Y., Du, Y. and Chen, G. (2023) Application of Single-Cell Sequencing to the Research of Tumor Microenvironment. Frontiers in Immunology, 14, Article 1285540.
https://doi.org/10.3389/fimmu.2023.1285540
[3] 程海波, 周仲瑛. 癌毒病机科学内涵的现代诠释[J]. 南京中医药大学学报, 2021, 37(5): 637-641.
[4] 卢红蓉, 杜松, 胡镜清. 痰瘀互结证治理论源流考[J]. 中医杂志, 2015, 56(10): 811-815.
[5] 李巧凤, 吴承玉. 痰瘀理论源流考[J]. 中华中医药杂志, 2024, 39(12): 6338-6341.
[6] 张一鸣, 王子健, 田辛晨, 等. 肝癌免疫抑制性肿瘤微环境的痰瘀病机与治疗策略[J]. 中医杂志, 2025, 66(14): 1444-1449.
[7] 叶招娣, 王丽华, 袁一顺, 等. 国医大师洪广祥肺癌病机理论与肿瘤微环境的相关性及中医药调控策略[J/OL]. 中华中医药学刊: 1-18.
https://link.cnki.net/urlid/21.1546.r.20260630.1420.002, 2026-09-18.
[8] Schreiber, R.D., Old, L.J. and Smyth, M.J. (2011) Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science, 331, 1565-1570.
https://doi.org/10.1126/science.1203486
[9] 李宇婷, 谭香玉, 黄柳娜, 等. 消化道肿瘤免疫抑制性微环境研究进展[J]. 四川大学学报(医学版), 2022, 53(1): 7-14.
[10] Wang, Z., Du, X., Xing, X., Xie, W., Xin, H. and Liu, W. (2025) Myeloid-Derived Suppressor Cells: Orchestrators of Tumor Immune Evasion and Therapeutic Vulnerabilities. Molecular Cancer Research, 23, 829-838.
https://doi.org/10.1158/1541-7786.mcr-25-0251
[11] Baessler, A. and Vignali, D.A.A. (2024) T Cell Exhaustion. Annual Review of Immunology, 42, 179-206.
https://doi.org/10.1146/annurev-immunol-090222-110914
[12] Wherry, E.J. and Kurachi, M. (2015) Molecular and Cellular Insights into T Cell Exhaustion. Nature Reviews Immunology, 15, 486-499.
https://doi.org/10.1038/nri3862
[13] 孙铜林, 邓瑶, 王立亚, 等. 从丹溪“相火-痰瘀”理论论治肺鳞癌的学术探究与临床实践[J]. 中医肿瘤学杂志, 2026, 8(2): 13-21.
[14] 田馨迪, 姚旭阳, 韩濡郁, 等. 肿瘤血管异常化的基础研究与临床应用进展[J]. 中国实用外科杂志, 2024, 44(6): 714-720.
[15] 陈纯辉, 孙学刚, 魏素芬, 等. 肿瘤微环境血瘀病机探讨[J]. 中西医结合研究, 2023, 15(3): 195-197.
[16] 马萌萌, 关徐涛, 张俊萍, 等. 基于“微型癥瘕”理论探讨肿瘤血管化现代生物学机制及“疏、消、补”治疗[J]. 世界科学技术-中医药现代化, 2026, 28(1): 276-287.
[17] 高卓维, 韩钦芮, 符秀琼, 等. 肿瘤微环境刚性的病机探讨[J]. 中国中医基础医学杂志, 2020, 26(12): 1808-1810.
[18] 陈袁嘉繁, 李亚星, 胡少博, 等. 基于肿瘤炎性-代谢-免疫微环境探讨肺癌从痰邪论治的作用机制[J]. 国际中医中药杂志, 2025, 47(10): 1341-1346.
[19] 周捷, 廖凌虹. 基于“伏痰”理论探讨巨噬细胞在肿瘤微环境中的作用及微观辨治[J]. 中医药通报, 2025, 24(12): 24-28.
[20] Hwang, B., Lee, J.H. and Bang, D. (2018) Single-Cell RNA Sequencing Technologies and Bioinformatics Pipelines. Experimental & Molecular Medicine, 50, 1-14.
https://doi.org/10.1038/s12276-018-0071-8
[21] Tao, Y., Ma, Y., Gu, L., Zhang, Y., Zhang, Q., Zhou, L., et al. (2025) Single-Cell RNA Sequencing Reveals Shen-Bai-Jie-Du Decoction Retards Colorectal Tumorigenesis by Regulating the TMEM131-TNF Signaling Pathway-Mediated Differentiation of Immunosuppressive Dendritic Cells. Acta Pharmaceutica Sinica B, 15, 3545-3560.
https://doi.org/10.1016/j.apsb.2025.05.013
[22] Yu, L., Dong, X., Yang, Q. and Dou, Y. (2026) Integrating Seropharmacology, Network Pharmacology, and Single-Cell Transcriptomics to Decipher the Dual Anti-Tumor Mechanisms of Astragalus Curcuma zedoaria in Lung Squamous Cell Carcinoma. Biomedical Chromatography, 40, e70482.
https://doi.org/10.1002/bmc.70482
[23] Wan, L., Hao, W., Li, L., Wang, L. and Song, Y. (2025) Dissecting Macrophage Heterogeneity and Kaempferol in Lung Adenocarcinoma: A Single-Cell Transcriptomic Approach and Network Pharmacology. Discover Oncology, 16, Article No. 104.
https://doi.org/10.1007/s12672-025-01832-9
[24] Li, Y., Peng, H., Zhou, S., Li, H., An, Y., Ruan, N., et al. (2026) Compounds and Monomeric Active Ingredients of Resolving Phlegm and Removing Stasis Therapy (RPST) for the Treatment of Non-Small Cell Lung Cancer: A Comprehensive Review. Journal of Ethnopharmacology, 356, Article 120770.
https://doi.org/10.1016/j.jep.2025.120770